2018 American Society of Hematology (ASH) Annual Meeting

The American Society of Hematology (ASH) is the world’s largest professional society serving clinicians and scientists who work to conquer blood diseases. The ASH Annual Meeting & Exposition brings together over 25,000 hematology professionals from around the world to discuss the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and immunologic, hemostatic and vascular systems.

This year, the ASH Meeting celebrated its 60th anniversary in San Diego, CA. As always, our team was proud to contribute new lymphoma discoveries for presentation at the meeting. Here are some research highlights from our team.


Dr. John Leonard led a global phase III clinical trial comparing the efficacy and safety of combined lenalidomide plus rituximab versus rituximab alone in people with previously treated indolent lymphoma, including follicular and marginal zone lymphoma. Results demonstrating lenalidomide-rituximab as an important new treatment option for this patient population.

Leonard


Dr. Richard Furman and colleagues found that at follow-up of up to seven years, ibrutinib demonstrated sustained activity in both first line and relapsed/refractory chronic lymphocytic leukemia (CLL) patients.

Furman2


Dr. Peter Martin led a study examining the safety and efficacy of CC-486, also known as oral azacitidine, plus R-CHOP chemotherapy in people with diffuse large B-cell lymphoma (DLBCL).

Martin.jpg


Using a combination of human, animal, and cell line data, Jude Phillip, PhD, of the Leandro Cerchietti Research Lab, and colleagues found that the internal architecture of lymphomas present important insights into disease progression.

Phillip.jpg


Dr. John Allan presented a preliminary update of an ongoing first-in-human study of vecabrutinib in patients with advanced B-cell malignancies.

Allan.jpg


Dr. Sarah Rutherford reported data that may support the elimination of bone marrow biopsies in follicular lymphoma and diffuse large B-cell lymphoma clinical trials.

Rutherford.jpg


Dr. Richard Furman and colleagues found that venetoclax is well tolerated and produces high levels of response in previously treated Waldenstrom’s macroglobulinemia patients.

Furman1


We are proud of our team’s continued commitment to advancing the overall understanding of lymphoma and improving clinical outcomes and quality of life for all those affected by the disease.

WCM/NYP Partners with LLS to Host Blood Cancer Survivorship Event

Thanks to a valued partnership with the Leukemia and Lymphoma Society (LLS), Weill Cornell Medicine and NewYork-Presbyterian Hospital (WCM/NYP) were proud co-hosts of “Life Beyond Blood Cancer,” a free educational event for patients and caregivers. The program explored various aspects of survivorship as experienced by people with lymphoma, leukemia, myeloma and other blood cancers.

The event drew in nearly 100 members of the New York metropolitan area’s blood cancer community for an evening of shared information and inspiration. Speakers included a range of experts across the WCM/NYP cancer care team, as well as blood cancer survivors who shared their experience and insight into living with Hodgkin lymphoma, chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

Here are a few highlights:

WCM/NYP Lymphoma Program Chief Dr. Peter Martin explained that innovative advancements in personalized medicine, immunotherapy, and targeted therapy have positively influenced blood cancer survival rates. Almost 1.5 million people in the United States are living with lymphoma, leukemia or myeloma. Dr. Martin noted that as patients are living longer, more clinical attention should be focused on treating the whole patient and his/her needs, as opposed to treating just the cancer cells within the body.

Alan Astrow, Chief of Hematology and Oncology at NewYork-Presbyterian Brooklyn Methodist Hospital, explained that a cancer diagnosis can affect a patient’s life in ways that exceed the strictly medical, and many patients welcome discussion about their spiritual, religious and existential concerns. Dr. Astrow advocated for increased communication between physicians and patients regarding spiritual needs, since a clear understanding of a patient’s hopes, fears and values can provide guidance when making decisions in the face of medical uncertainty.

Kelly Trevino, PhD, a clinical psychologist at WCM/NYP with a specialization in psychosocial oncology, discussed strategies for managing the anxiety that often accompanies a cancer diagnosis. Threatening situations like cancer can lead to worry and nervousness, muscle tension, shortness of breath, tingling/numbness and difficulty concentrating – all of which can have a negative impact on quality of life. Coping strategies include deep breathing, progressive muscle relaxation, pursuit of distracting activities and even scheduled “worry time” to prevent anxious thoughts from infiltrating the entire day.

Three survivors across varying ages and diagnoses then shared the ups and downs of their treatment and post-treatment journeys and provided the audience with insight into life beyond cancer.

We at Weill Cornell Medicine and NewYork-Presbyterian Hospital are honored to be able to offer educational programs and resources to people affected by cancer, and we are committed to doing our best to address the needs of our patient community throughout all stages of the cancer journey.

LLS
The event concluded with an interactive question-and-answer session between the speakers and audience, moderated by WCM/NYP outpatient oncology social worker Susan Marchal, LCSW.

 

OncLive State of the Science Summit

We’re proud to share that Dr. Peter Martin and Dr. John Leonard are co-hosting a State of the Science Summit on Hematologic Malignancies with OncLive in Queens on May 4, 2017.

This free event will feature educational sessions and a dinner and networking reception. All healthcare practitioners are welcome. Seats are limited, so register today: http://ow.ly/dfIx308iTis

OncLive State of the Science Agenda_Flyer